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Introduction
Pneumonia cases in 2006 collectively contributed to 1.2 million 
hospitalizations, which eventually led to over 55,000 patient 
deaths in the same year from the disease. When combined 
with influenza, pneumonia is the eighth leading cause of death 
in the US. Approximately 5.6 million US patients are infected 
with community-acquired bacterial pneumonia (CABP) 
annually, contributing to costs exceeding $12 billion yearly.1
CABP is defined as an alveolar infection that develops in 
the outpatient setting or within 48 hours of hospital admis-
sion and is primarily caused by Streptococcus pneumoniae; how-
ever, other culprits include Haemophilus influenzae, Moraxella 
catarrhalis, Mycoplasma pneumoniae, and Chlamydophila 
pneumoniae.1 In contrast, healthcare-associated pneumonia 
(HCAP) cases are mainly infected by Legionella pneumo-
phila, Staphylococcus aureus, or other bacteria.2 The specific 
pathogenic organisms vary by patient populations and may 
be influenced by the disease states of the patient. This can 
be additionally challenging for practitioners to identify and 
appropriately treat since certain risk factors and comorbidi-
ties (eg, alcoholism, COPD, smoking, aspiration, and HIV 
infection) can make patients more susceptible to uncommon 
causative organisms.2
Physician adherence to the Infectious Diseases Society 
of America/American Thoracic Society (IDSA/ATS) treat-
ment guidelines for CABP is paramount because it improves 
patient outcomes. According to the current IDSA/ATS 
treatment guidelines for CABP, there are different empiric 
treatment options for CABP in the outpatient setting. Non-
hospitalized patients who are otherwise healthy should receive 
monotherapy with a macrolide or doxycycline. In those with 
comorbid conditions such as the presence of chronic disease, 
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recent antimicrobial use, or risk factors for drug-resistant 
S. pneumoniae, a respiratory fluoroquinolone (levofloxacin, 
moxifloxacin, or gemifloxacin) or a β-lactam plus a macrolide 
is recommended. If a patient is admitted to the hospital, a 
respiratory fluoroquinolone or a macrolide plus a β-lactam is 
suggested. Additional antibiotic selection can be tailored to 
the suspected bacteria, patient risk factors, and environmental 
risk factors (eg, admission to the intensive care unit). Prac-
titioners should encourage smoking cessation and promote 
pneumococcal and influenza vaccinations in order to aid in 
the prevention of CABP.2,3
In the last several years, owing to concerns regarding 
multidrug-resistant organisms (MDROs), a new antibiotic 
has been developed and approved for use in the treatment 
of CABP. Ceftaroline fosamil (Teflaro®) was approved by 
the US Food and Drug Administration (FDA) in October 
2010. Ceftaroline fosamil is a new extended-spectrum 
cephalosporin, β-lactam antibiotics, with activity against 
methicillin-resistant Staphylococcus aureus (MRSA) and 
penicillin-resistant Streptococcus pneumoniae.3–5 It also has 
Gram-negative coverage against Escherichia coli, Proteus 
mirabilis, H. influenzae, M. catarrhalis, Neisseria meningitidis, 
as well as wild-type Enterobacteriaceae, but has no activity 
against anaerobes. This review summarizes ceftaroline 
fosamil’s pharmacokinetic and pharmacodynamic pro-
file, clinical efficacy and safety, and place in therapy for the 
treatment and management of CABP.
Mechanism of Action
Ceftaroline fosamil is classified as a fifth-generation cepha-
losporin. It is a prodrug that was developed by modifying the 
structure of a fourth-generation cephalosporin, cefozopran.5–7 
The antibacterial activity of ceftaroline occurs through bind-
ing to penicillin-binding proteins (PBPs) and interrupting 
cell wall synthesis, similar to other β-lactam antibiotics.7–9 
It binds to PBPs 1–4 with an especially high affinity for PBP2a, 
which is associated with methicillin resistance. An oxine ring 
provides ceftaroline with activity against β-lactamase pro-
ducing microorganisms and a 1,2,4-thiadiazole ring gives it 
Gram-negative activity. Ceftaroline provides improved activ-
ity against S. aureus and S. pneumoniae as a result of the 3′ 
side chain mediating improved binding to PBPs that exhibit 
decreasing binding affinity for standard β-lactams.10
Antimicrobial Activity
Ceftaroline exhibits both bactericidal and time-dependent 
killing activity.4 Antimicrobial effects are a result of binding 
and irreversible inactivation of essential PBPs, leading to the 
inhibition of bacterial cell-wall biosynthesis, lysis, and death. 
It has a broad spectrum of activity including both Gram-
positive and Gram-negative bacteria as well as MRSA.8 The 
spectrum of activity against Gram-negative bacilli is similar 
to that seen with ceftriaxone.11 Susceptible bacterial isolates 
from patients enrolled in the FOCUS 1 and 2 studies along 
with the minimum inhibitory concentration (MIC) ranges 
are listed in Table 1.12 Ceftaroline has a bacterial spectrum 
of activity against organisms that are commonly associated 
with CABP including S. pneumoniae, S. aureus, H. influenzae, 
M. catarrhalis, and Klebsiella pneumoniae, but does not pos-
sess activity against atypical pathogens.12 Resistance to CABP 
pathogens has been an increasing concern, promoting the 
need for the development of newer antibiotics for the treat-
ment of CABP. A 12-year analysis of pneumococcal resistance 
rates has shown an increase in resistance to commonly used 
β-lactam agents.4,10,11,13
The Gram-positive anaerobic activity of ceftaroline is 
similar to that seen with amoxicillin-clavulanate.9 It has lim-
ited activity against the Bacteroides fragilis group, but does have 
coverage against β-lactamase negative strains. In addition to 
activity against MRSA, ceftaroline exhibits in vitro activity 
against vancomycin-intermediate and vancomycin-resistant 
S. aureus.8 Ceftaroline has limited activity against Enterococcus 
faecalis, Enterococcus faecium, and Corynebacterium jeikeium.
Ceftaroline is still susceptible to extended spectrum 
β-lactamases, cephalosporinases, and carbapenemases.14 There 
are current ongoing studies on the drug in combination with 
the β-lactamase inhibitor, avibactam, in order to expand its 
antimicrobial coverage.4,14 The addition of avibactam restores 
ceftaroline’s activity against Enterobacteriaceae strains that 
are resistant to other broad spectrum β-lactam antibiotics.
Pharmacokinetics
Following intravenous (IV) administration, the conversion of 
the prodrug ceftaroline fosamil to active form ceftaroline is 
dependent upon metabolism by phosphatase enzymes in the 
plasma.5–7 A small portion of the active drug then under-
goes metabolism via hydrolysis to the β-lactam ring to form 
an inactive metabolite, ceftaroline-M-1.9 Ceftaroline and its 
metabolites are primarily eliminated by the kidneys with a 
renal clearance of 95.6 and 86.7 mL/minute for single and 
multiple doses, respectively.5,9,15 Approximately 88% of the 
drug was found in the urine and 6% in the feces 48 hours fol-
lowing the administration of a 600 mg dose,.5,8 In vitro stud-
ies indicate that ceftaroline is not metabolized by cytochrome 
P-450 isoenzymes, resulting in less drug interactions and no 
dosing adjustments for impaired hepatic function.4
table 1. Antimicrobial spectrum of activity.12,18–21
oRgAniSM MiC RAngE (Mg/l)
S. pneumoniae #0.015–0.12
S. pneumoniae (multidrug resistant) #0.015–0.12
S. aureus 0.12–0.5
H. influenzae #0.015–0.5
Haemophilus parainfluenzae #0.015–1
E. coli 0.03–.16
K. pneumoniae 0.06–0.5
Ceftaroline fosamil in CABP
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Single and multiple dose studies show that ceftaroline 
displays linear pharmacokinetics with proportional increases 
in the maximum concentration (Cmax) and area under the 
plasma drug concentration-time curve (AUC) with increases 
in dose.8,14,15 In a double-blind, placebo-controlled multiple-
ascending dose study, the AUC and Cmax of ceftaroline 
increased proportionately with dose following the IV admin-
istration of 300 or 600 mg every 12 hours or 800 mg every 
24 hours for multiple days.16,17 There has been shown to be no 
ceftaroline accumulation following the administration of mul-
tiple doses at either 12 or 24 hours for up to 14 days.7 Plasma 
protein binding is approximately 20% and decreases with 
increasing concentrations.6,7,9 The median steady-state volume 
of distribution following a single 600 mg dose is 20.3 L with 
a range of 18.3–21.6 L, which is similar to extracellular fluid 
volume, indicating distribution into total body fluids. Body 
weight is a predictor of volume of distribution while creatinine 
clearance (CrCl) can be used to predict drug elimination.8
The elimination half-life of ceftaroline is estimated to be 
2.6 hours in patients with normal renal function; the half-
life of the inactive metabolite is 4.5 hours.5–7,9 The AUC and 
half-life increase by an estimated 25 and 14%, respectively, 
in patients with mild renal impairment (estimated CrCl 
50–80 mL/minute), and the AUC increases by up to 50% in 
patients with moderate to severe renal impairment (estimated 
CrCl 30–50 mL/minute).5,6 Therefore, dosage adjustment 
is recommended in patients with moderate to severe renal 
impairment and with end-stage renal disease (ESRD) receiv-
ing hemodialysis (estimated CrCl 15–50 mL/minute). The 
manufacturer recommends that ceftaroline doses be scheduled 
for administration following dialysis as the drug is removed 
during hemodialysis.5 In vitro studies indicate that ceftaroline 
is not metabolized by cytochrome P-450 isoenzymes, result-
ing in less drug interactions and no adjustments for impaired 
hepatic function.4
Elderly patients may require a dosage adjustment for cef-
taroline fosamil because of age-related changes in renal func-
tion.5 The mean AUC and half-life were shown to be increased 
by 33 and 41%, respectively, in healthy elderly patients ($65 
years of age) compared to healthy young adults (18–45 years of 
age) following a single 600 mg dose.5
There is limited data establishing the safety and efficacy 
of ceftaroline fosamil in pediatric patients (,18 years of age).5 
The pharmacokinetics of ceftaroline are similar in adoles-
cents to those observed in healthy adult patients. In patients 
of 12–17 years of age with normal renal function, the mean 
plasma clearance and volume of distribution following an 
8 mg/kg dose were similar to those observed in healthy adult 
subjects after receiving a 600 mg dose. However, Cmax and 
AUC were reduced by 10 and 23%, respectively.5
Pharmacodynamics
Ceftaroline exhibits bactericidal, time-dependent, and 
concentration-independent killing.6,8 The primary predictor of 
bacteriologic and clinical efficacy is the percentage of time that 
the free drug remains above the MIC for the pathogen.8 The 
time the free drug remains above the MIC for staphylococci 
is 30% of the total administration time for ceftaroline to be 
bacteriostatic and 40% for S. pneumoniae and Gram-negative 
bacilli.4,8,9 Ceftaroline demonstrates bactericidal activity when 
the time the free drug remains above the MIC reaches 50% 
in staphylococci and 60% in Gram-negative bacilli. Neither 
protein binding nor methicillin and penicillin resistance have 
been shown to affect this parameter. Ceftaroline demonstrates 
a limited post-antibiotic effect against most pathogens except 
S. aureus, against which it has been shown to possess a longer 
effect.
clinical efficacy
The FOCUS 1 and FOCUS 2 clinical trials are randomized, 
double-blind, and multicenter phase III studies evaluating the 
safety and efficacy of ceftaroline fosamil when compared to 
ceftriaxone for the treatment of patients with CABP. Results 
of the FOCUS 1 and 2 studies are summarized in Tables 2 
and 3. Study participants were randomized (1:1) to receive 
drug therapy for 5–7 days of either ceftaroline fosamil 600 mg 
every 12 hours or ceftriaxone 1 g every 24 hours if they were 
hospitalized with CABP, requiring IV therapy, and having a 
pneumonia outcomes research team (PORT) risk class score 
of III or IV. The FOCUS 1 and FOCUS 2 clinical trials were 
intended as parallel, methodologically similar (with the exclu-
sion of two doses of clarithromycin given on day 1 during 
FOCUS 1 only) comparative analyses, which did not permit 
change to oral medications for drug therapy completion.3,18,19
The primary endpoint of the FOCUS program was to 
determine the non-inferiority of ceftaroline fosamil in clinical 
cure rates when compared with ceftriaxone in the clinically 
evaluable (CE) and modified intent-to-treat efficacy (MITTE) 
populations at the test-of-cure (TOC) visit. A clinical cure 
was defined as an afebrile condition for 24 consecutive hours 
and conclusion of signs and symptoms of CABP or determi-
nation that antibiotic therapy was no longer necessary, and a 
relapse was defined as the return of symptoms requiring anti-
biotics during the late follow-up (LFU) visit.3,20 The TOC 
visit occurred 8–15 days from the last dose of study medica-
tion administered, and then the LFU occurred 21–35 days 
from the last dose of study medication.3,20
table 2. Clinical cure rates in CE patients.
CEFtARolinE  
gRouP
CEFtRiAxonE  
gRouP
diFFEREnCE,  
(95% ConFidEnCE 
intERvAl [Ci])
FOCus 1 86.6% 78.2% 8.4%, (1.4–15.4%)
FOCus 2 82.1% 77.2% 4.9%, (−2.5–12.5%)
Integrated  
efficacy  
analysis
84.3% 77.7% 6.7%, (1.6–11.8%)
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The FOCUS 1 clinical cure rates in CE patients were 
86.6% in the ceftaroline fosamil group versus 78.2% in the 
ceftriaxone group (difference, 8.4%; 95% confidence interval 
[CI], 1.4–15.4%). During FOCUS 2, the clinical cure rates 
in the CE population were 82.1% in the ceftaroline fosamil 
group versus 77.2% in the ceftriaxone group (difference, 4.9%; 
95% CI, −2.5–12.5%). In the integrated efficacy analysis of 
the two trials, the clinical cure rates in the CE population 
were 84.3% in the ceftaroline fosamil group versus 77.7% in 
the ceftriaxone group (difference, 6.7%; 95% CI, 1.6–11.8%). 
Hence, non-inferiority was established for ceftaroline fosamil 
when compared to ceftriaxone. Refer to Table 2.3,9,18,19
The FOCUS 1 clinical cure rates in MITTE patients 
were 83.8% in the ceftaroline fosamil group versus 77.7% in 
the ceftriaxone group (difference, 6.2%; 95% confidence inter-
val [CI], −0.2–12.6%). During FOCUS 2, the clinical cure 
rates in the MITTE population were 81.3% in the ceftaroline 
fosamil group versus 75.5% in the ceftriaxone group (differ-
ence, 5.9%; 95% CI, −1.0–12.7%). The integrated summary 
reports clinical cure rates in MITTE patients as 82.6 versus 
76.6% for ceftaroline fosamil and ceftriaxone, respectively 
(difference, 6.0%; 95% CI, 1.4–10.7%), proving ceftaroline 
fosamil to be non-inferior to therapy with ceftriaxone. Refer 
to Table 3.3,9,18,19
Clinical cure rates for the study medication, ceftaroline 
fosamil, were found to be non-inferior to those of ceftriaxone 
across all predefined study groups during the entire FOCUS 
program. Furthermore, clinical relapse rates at the time of 
LFU were similar between the two study populations for the 
CE and MITTE groups as described in the integrated analysis. 
Therefore, comparable efficacy of ceftaroline fosamil 600 mg 
administered intravenously every 12 hours was established to 
ceftriaxone 1 g administered intravenously every 24 hours in 
hospitalized patients with CABP requiring IV therapy and 
having a PORT risk class score of III or IV.3,9,18,19
tolerability and safety
Over the course of the FOCUS 1 and FOCUS 2 phase III 
clinical trials, all enrolled patients (1228 total patients) were 
followed for treatment-emergent adverse events (TEAEs). Six-
hundred and thirteen patients were monitored from the first 
IV administration of ceftaroline fosamil until the TOC visit, 
and 615 patients were equally monitored in the ceftriaxone 
group. Patients who were administered any amount of study 
medication were included in the safety analysis. Also, serious 
adverse events (SAEs) including deaths that transpired within 
30 days of the last study medication dose received and/or up to 
the LFU visit were reported. Study medication mean exposure 
was 6.5 ± 1.1 days for both study populations. Patients partici-
pated in scheduled laboratory visits from initiation until the 
TOC visit, while unscheduled laboratory visits were utilized 
until the LFU visit.3,18,19,21
The following safety results are documented from the 
integrated summary report of the FOCUS 1 and FOCUS 2 
clinical studies. The most often reported TEAEs in the cef-
taroline fosamil treatment population were diarrhea (4.2%), 
headache (3.4%), and insomnia (3.1%). Approximately 75% of 
patients noticed only mild TEAEs or no TEAEs in either 
treatment population; therefore, the severity-based distribu-
tion of TEAEs was consistent between the two treatment 
populations. The overall incidence rates of adverse events 
(AEs) were comparable between the ceftaroline fosamil and 
ceftriaxone populations, respectively: patients experiencing at 
least one TEAE (47.0 vs. 45.7%), SAE (11.3 vs. 11.7%), dis-
continuation because of an AE (4.4 vs. 4.1%), or death (2.4 vs. 
2.0%).3,21
Twenty-seven total deaths occurred throughout the 
FOCUS studies; 15 in the ceftaroline fosamil population and 
12 in the ceftriaxone population. Of the deaths recorded, the 
investigator classified them by type or organ system. Two deaths 
(one from each population) could have been linked to study 
medication when appraised by the investigator. Deaths associ-
ated with cardiac disorders (2 vs. 7), infections and infestations 
(3 vs. 1), neoplasms (4 vs. 0), respiratory disorders (4 vs. 3), 
and general disorders such as sudden death and multiple organ 
disorder (2 vs. 1) occurred in the ceftaroline fosamil and cef-
triaxone treatment arms, respectively.3,21
Seven SAEs were recorded in more than two patients 
from the ceftaroline fosamil group, which included pneumo-
nia (as defined by worsening or relapse of CABP or nosoco-
mial pneumonia, nine patients), pleural effusion (five patients), 
pulmonary embolism (five patients), chronic obstructive pul-
monary disease (four patients), pyothorax (four patients), 
respiratory failure (four patients), and malignant lung neo-
plasm (three patients). The investigator assessed the SAEs, 
and the majority (95.7% in the ceftaroline fosamil population 
and 91.7% in the ceftriaxone population) were disregarded 
as not related to the study medication. Therefore, no safety 
concerns were expressed. No occurrence of TEAE was docu-
mented in more than two subjects in the ceftaroline fosamil 
population, leading to the discontinuation of the study medi-
cation or withdrawal from the clinical trial. However, pneu-
monia (as defined above), pulmonary embolism, respiratory 
failure, septic shock, and sudden death each occurred in two 
patients in the ceftaroline fosamil population, which led to 
the discontinuation of the study medication or withdrawal 
from the clinical trial for these reported cases. Ten patients 
table 3. Clinical cure rates in MITTE patients.
CEFtARolinE  
gRouP
CEFtRiAxonE  
gRouP
diFFEREnCE,  
(95% ConFidEnCE 
intERvAl [Ci])
FOCus 1 83.8% 77.7% 6.2%, (−0.2–12.6%)
FOCus 2 81.3% 75.5% 5.9%, (−1.0–12.7%)
Integrated  
efficacy  
analysis
82.6% 76.6% 6.0%, (1.4–10.7%)
Ceftaroline fosamil in CABP
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in the ceftaroline fosamil population and nine patients from 
the ceftriaxone population either stopped the study medica-
tion or withdrew from the study. The aforementioned SAEs 
and TEAEs leading to the discontinuation of the study medi-
cation revealed an inadequate therapeutic response, which 
caused prolonged hospitalizations (meets criteria of the SAE 
definition) or represented AEs that resulted in death (with-
drawal from the study).3,21
In general, ceftaroline fosamil was found to be safe and 
well tolerated overall. The use of ceftaroline fosamil did not 
possess any unexpected safety considerations. Ceftaroline fos-
amil is classified as pregnancy category B. There are no well-
controlled studies on pregnant women, and it is unknown if 
ceftaroline is excreted in breast milk.5 Therefore, it is recom-
mended by the manufacturer that ceftaroline fosamil only be 
prescribed if the potential benefit justifies the potential risk to 
the fetus.
Prescribers should exercise caution in patients with past 
allergic skin reactions to any other β-lactam antibiotics and 
ceftaroline fosamil should be immediately stopped if a reaction 
develops. Ceftaroline fosamil has a similar safety and tole-
rability profile as observed with ceftriaxone and other agents 
of the cephalosporin class.3,5,21
dosage and Administration
Ceftaroline fosamil is available in 600 and 400 mg reconstitut-
able vials of powder for injection.5 The recommended dose in 
adults (greater than or equal 18 years of age) with normal renal 
function (CrCl greater than 50 mL/minute) is 600 mg every 
12 hours by IV infusion administered over one hour. Recom-
mended duration of therapy for CABP is 5–7 days based on 
the severity of the infection and response to therapy.
Dosing adjustment of ceftaroline fosamil is required 
in patients with impaired renal function and patients with 
ESRD on intermittent hemodialysis.5,7,15 Patients with mild 
to moderate renal impairment have an increased AUC of 19 
and 52%, respectively, with an increased half-life of 27 and 
58%, respectively, after the infusion of a single 600 mg dose. 
The Cmax was unaltered in patients with mild or moderate 
renal impairment, but was slightly higher in subjects with 
severe renal impairment as compared to patients with normal 
renal function. Therefore, it is recommended that the dosage 
be adjusted to 400 mg every 12 hours in patients whose CrCl 
is greater than 30 but less than or equal to 50 mL/minute, and 
further decreased to 300 mg every 12 hours in patients whose 
CrCl is greater than or equal to 15 mL/minute but less than or 
equal to 30 mL/minute, and then decreased to 200 mg every 
12 hours in patients whose CrCl is less than 15 mL/minute 
with ESRD, including patients receiving hemodialysis.5,8,15
Patients receiving intermittent hemodialysis, after receiv-
ing a single 400 mg dose of ceftaroline fosamil, had a 167% 
higher mean AUC as compared to patients with normal renal 
function.7,8 Additionally, the Cmax was 74% higher and the 
half-life was approximately 123% longer. Following a four 
hour hemodialysis session, 21.6% (76 mg) of ceftaroline was 
measured in the dialysate. Therefore, ceftaroline fosamil should 
be administered following hemodialysis on dialysis days.5,7,15
Place in Therapy
The FOCUS trials established that ceftaroline fosamil was 
non-inferior to ceftriaxone in the treatment of non-ICU 
patients with CABP; however, it has not been established 
as preferred use even though the integrated analysis by File 
et al. found that ceftaroline demonstrated superiority in 
most of the FOCUS study groups and subgroups.18–20 The 
Average Wholesale Price of one vial of ceftaroline fosamil 
is $41, which corresponds to about $80 per day for therapy, 
and the total cost of treatment is higher as compared to other 
common treatments such as IV cephalosporins and respira-
tory fluoroquinolones; additionally, no cost-benefit studies 
of ceftaroline fosamil in the treatment of CABP have been 
conducted.
Ceftaroline fosamil does represent a new treatment option 
for the indication of CABP in the setting of patients at risk for 
MDROs. Antimicrobial resistance, an aging population, and 
concomitant comorbidities in the community have changed 
prescribing practices for CABP. Initial therapy in the inpatient 
setting may consist of combination therapy and antimicrobial 
coverage of resistant pathogens.6 Utilization of local antibio-
grams and knowledge of resistance patterns in the community 
will help to guide selection of antimicrobial agents. Ceftaroline 
provides antimicrobial activity against wild-type and mutant 
pathogens responsible for CABP, exhibiting lower MICs for 
S. aureus and S. pneumoniae as compared to ceftriaxone and 
other cephalosporins. Advantages of ceftaroline include its 
dosing, minimal drug interaction profile, and low resistance 
to common CABP pathogens, making it an alternative for 
patients unable to tolerate or respond to other antimicrobial 
therapies. Patients identified as MRSA colonized or having 
experienced past episodes of drug-resistant S. pneumoniae may 
benefit from treatment with ceftaroline fosamil initially for 
CABP, though there are no current clinical data to support its 
use in this population.3,7
conclusion
Ceftaroline fosamil represents a new treatment option for 
patients with CABP, possessing antimicrobial activity against 
both Gram-positive and Gram-negative bacteria. Antimi-
crobial treatment for CABP has changed over the years as a 
result of antibiotic resistance, an aging population, and patient 
comorbidities.6 Ceftaroline fosamil has been labeled as the 
first new antibiotic in the IDSA initiative to develop ten new 
antibiotics by the year 2020.22 Practitioners should reserve 
this antibiotic for patients with risk factors for pathogens with 
resistance to other antimicrobials that are more cost effective. 
It does have a spectrum of activity that covers typical patho-
gens in CABP, but its role in treatment should be reserved for 
those patients with a high risk of MDROs.
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